首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, ^z>Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Fruh,

【24h】

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, ^z>Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Fruh,

机译：ALK阳性非小细胞肺癌（NSCLC）患者的临床结果（NSCLC）患者DE Novo EGFR或KRAS共突变接受酪氨酸激酶抑制剂（TKIS）Sabine Schmid，Oliver Gautschi，Saha Rothschild，^ Z> Michael Mark，Patrizia Frosech， Dirk Klingbiel，Hermann Reichegger，Wolfram Jochum，Joachim Diebold，Martin Fruh，

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

http://dx.doi.org/10.1016/jjtho.2016.12.003

机译：HTTP://东西.do i.org/10.1016/结局挺好哦.2016.12.003

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第4期|共8页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
NSCLC; ALK/KRAS; ALK/EGFR; Co-alteration; TKI treatment; Outcome;

机译：NSCLC;ALK / KRAS;ALK / EGFR;共同改变;TKI治疗;结果;

相似文献

外文文献

1. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, ^z>Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Fruh, [J] . Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第4期

机译：ALK阳性非小细胞肺癌（NSCLC）患者的临床结果（NSCLC）患者DE Novo EGFR或KRAS共突变接受酪氨酸激酶抑制剂（TKIS）Sabine Schmid，Oliver Gautschi，Saha Rothschild，^ Z> Michael Mark，Patrizia Frosech， Dirk Klingbiel，Hermann Reichegger，Wolfram Jochum，Joachim Diebold，Martin Fruh，
2. PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI) [J] . Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：PUB100非小细胞肺癌（NSCLC）临床结果（NSCLC）患者ALK共突（EGFR或KRA）接受酪氨酸激酶抑制剂（TKI）
3. Genotypic and histological evolution of non-small cell lung cancers (NSCLC) with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) [évolution histologique et génotypique des cancers bronchiques non à petites cellules (CBNPC) avec résistance acquise sous TKI EGFR] [J] . WislezM. Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer . 2011,第12期

机译：对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）获得性耐药的非小细胞肺癌（NSCLC）的基因型和组织学演变EGFR]
4. Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI [O] . Liping Lin, Juanjuan Zhao, Jiazhu Hu, 2018

机译：一线用EGFR-TKI治疗的体重减轻对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）敏感突变晚期非小细胞肺癌（NSCLC）存活率的影响
5. PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI) [O] . Sabine Schmid, Oliver Gautschi, Sacha Rothschild, 2017

机译：PUB100非小细胞肺癌（NSCLC）临床结果（NSCLC）患者ALK共突（EGFR或KRA）接受酪氨酸激酶抑制剂（TKI）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号